Wherever you go (well, we aren’t going now) but Corona is the thing we first hear. Of late we’ve been hearing so many people are plagued by this and so many have died. But trust me, this article is something good to read.
So the joyful part is that the US starts the first Human trial of the vaccine. Yes, that’s true. What you’ve read is absolutely right. With support from India and Norway, the US has begun the first phase of clinical trials. The trial began at the Kaiser Permanente Washington Health Research Institute (KPWHRI) in Seattle as the first participant received the investigational vaccine.
One thing that we’ve to keep in mind is that it may be around 18 months until the vaccine comes out once it has passed more trial phases to prove it works and is safe.
“I’m pleased to report today that a vaccine candidate has begun the phase one clinical trial. This is one of the fastest vaccine development launches in history. Not even close. We’re also racing to develop antiviral therapies and other treatments,” Trump told reporters at a White House news conference on Monday.
Named mRNA-1273, The vaccine was developed by US National Institutes of Health (NIH) scientists at biotechnology company Moderna, which is based in Cambridge, Massachusetts.
In its website, CEPI so far has secured USD 760 million toward its USD 1 billion funding target, with multi-year funding from Norway, UK, Germany, Japan, Canada, Ethiopia, Australia, the Bill & Melinda Gates Foundation, and Wellcome Trust. The open-label trial will enroll 45 healthy adult volunteers aged 18 to 55 years over approximately six weeks.
The virus affected over 175,000 and has claimed over 7000 deaths.
Anthony Fauci, head of infectious diseases at the NIH said that finding a secure and effective cure for this is at the highest most priority, thus preventing the infection.”This Phase 1 study, launched in record speed, is a crucial initiative toward achieving that goal.”
The trial includes keeping a track of various doses delivered by intramuscular injection in the upper arm, with participants monitored for side-effects like soreness or fever.
The Phase 1 trial is led by Lisa A Jackson, MD, a senior investigator at KPWHRI. Study participants will receive two doses of the vaccine via injection in the upper arm, approximately 28 days apart. They assign each participant to receive a 25 microgram (mcg), 100 mcg or 250 mcg dose at both vaccinations, with 15 people in each dose cohort, according to a press release.
The first four participants will receive one injection with a low dose, and also the next four participants will receive the 100 mcg dose. Investigators will review safety data before vaccinating the remaining participants in the 25 and 100 mcg dose groups and before participants receive their second vaccinations. They will do another safety review before they enroll participants in the 250 mcg cohort.
According to the World Health Organization (WHO), 80 percent of COVID-19 cases are mild, 14 percent are severe and about five percent result are critical, leading to a severe respiratory disorder that causes the lungs to fill with fluid which in turn prevents oxygen from reaching organs.
Patients with mild cases recover during a week or two, while severe cases can take six or more weeks. Recent estimates suggest about one percent of all infected people die.